<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35325">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02136420</url>
  </required_header>
  <id_info>
    <org_study_id>497997</org_study_id>
    <nct_id>NCT02136420</nct_id>
  </id_info>
  <brief_title>Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels</brief_title>
  <official_title>Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faisal Karmali</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Space Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Schepens Eye Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adaptation to altered gravity has been of concern from the earliest reports of space motion
      sickness, through the Apollo exploration era, and into current planning of exploration
      missions. The proposed research program takes a new approach which could lead to an
      effective, practical and acceptable protocol for preadapting astronauts to space flight. By
      using the gravito-inertial alterations possible with centrifugation in different body
      orientations the investigators will quantify an individual's sensory adaptation capability
      and use it to predict and to minimize the consequences of movement in any other gravity
      environment - eventually including weightlessness. The investigators will also study whether
      a drug (promethazine) affects motion perception and motion sickness.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Rate of recovery of roll tilt perception errors after exposure to hypergravity</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Vestibular</condition>
  <arm_group>
    <arm_group_label>Training, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No training, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subject does test with no hyper gravity training and placebo drug only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training, promethazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>promethazine 25 mg, one time 120 minutes prior to experiment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No training, promethazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>promethazine 25 mg, one time 120 minutes prior to experiment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine</intervention_name>
    <description>Subject receives promethazine</description>
    <arm_group_label>Training, promethazine</arm_group_label>
    <arm_group_label>No training, promethazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hyper gravity training</intervention_name>
    <description>Subject receives hypergravity training before testing</description>
    <arm_group_label>Training, placebo</arm_group_label>
    <arm_group_label>Training, promethazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Training, placebo</arm_group_label>
    <arm_group_label>No training, placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No hypergravity training</intervention_name>
    <description>Subjects do not receive normal Earth gravity</description>
    <arm_group_label>No training, placebo</arm_group_label>
    <arm_group_label>No training, promethazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be in general good health

        Exclusion Criteria:

          -  Anyone who is not generally in good general health does not qualify

          -  Cardiovascular disease

          -  Severe diabetes

          -  Respiratory condition (e.g. asthma or emphysema)

          -  Narrow angle glaucoma

          -  Prostatic hypertrophy

          -  Gastrointestinal disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faisal Karmali, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faisal Karmali, Ph.D.</last_name>
    <phone>617-573-5593</phone>
    <email>faisal_karmali@meei.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Schepens Eye Research Institute</investigator_affiliation>
    <investigator_full_name>Faisal Karmali</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Motion Sickness</mesh_term>
    <mesh_term>Space Motion Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
